Stratos Wealth Partners LTD. Buys Shares of 1,801 Quest Diagnostics Inc (NYSE:DGX)

Stratos Wealth Partners LTD. bought a new stake in Quest Diagnostics Inc (NYSE:DGX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 1,801 shares of the medical research company’s stock, valued at approximately $200,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. boosted its position in shares of Quest Diagnostics by 2,638.3% in the first quarter. BlackRock Inc. now owns 15,362,418 shares of the medical research company’s stock valued at $1,508,435,000 after buying an additional 14,801,397 shares during the last quarter. MARSHALL WACE ASIA Ltd bought a new stake in Quest Diagnostics during the first quarter worth about $74,201,000. Marshall Wace North America L.P. bought a new stake in Quest Diagnostics during the first quarter worth about $74,201,000. Renaissance Technologies LLC raised its stake in Quest Diagnostics by 755.2% in the first quarter. Renaissance Technologies LLC now owns 503,700 shares of the medical research company’s stock worth $49,458,000 after buying an additional 444,800 shares during the period. Finally, Janus Capital Management LLC raised its stake in Quest Diagnostics by 34.2% in the first quarter. Janus Capital Management LLC now owns 1,339,007 shares of the medical research company’s stock worth $131,477,000 after buying an additional 341,476 shares during the period. Institutional investors own 90.97% of the company’s stock.

Quest Diagnostics Inc (DGX) opened at 106.10 on Friday. The company has a market cap of $14.47 billion, a price-to-earnings ratio of 21.38 and a beta of 0.69. The company’s 50-day moving average is $108.82 and its 200 day moving average is $103.03. Quest Diagnostics Inc has a 12 month low of $79.12 and a 12 month high of $112.97.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Tuesday, July 25th. The medical research company reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.13. Quest Diagnostics had a return on equity of 16.60% and a net margin of 10.65%. The firm had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter in the prior year, the firm posted $1.34 EPS. The business’s revenue was up 1.9% on a year-over-year basis. Equities analysts forecast that Quest Diagnostics Inc will post $5.70 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Monday, July 24th. Shareholders of record on Monday, July 10th were given a dividend of $0.45 per share. This represents a $1.80 dividend on an annualized basis and a yield of 1.70%. The ex-dividend date of this dividend was Thursday, July 6th. Quest Diagnostics’s dividend payout ratio (DPR) is currently 36.29%.

COPYRIGHT VIOLATION NOTICE: “Stratos Wealth Partners LTD. Buys Shares of 1,801 Quest Diagnostics Inc (NYSE:DGX)” was posted by Stock Observer and is the property of of Stock Observer. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2017/08/12/stratos-wealth-partners-ltd-buys-shares-of-1801-quest-diagnostics-inc-nysedgx.html.

A number of analysts have recently issued reports on the stock. UBS AG reissued a “buy” rating and issued a $115.00 price target (up from $102.00) on shares of Quest Diagnostics in a research report on Tuesday, April 25th. Zacks Investment Research raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating and set a $122.00 price target for the company in a research report on Tuesday, June 6th. Mizuho reissued a “buy” rating and issued a $90.00 price target (down from $103.00) on shares of Quest Diagnostics in a research report on Friday, April 14th. BidaskClub raised shares of Quest Diagnostics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 29th. Finally, ValuEngine raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Quest Diagnostics presently has an average rating of “Hold” and an average target price of $109.62.

In other Quest Diagnostics news, SVP Catherine T. Doherty sold 59,762 shares of the company’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $107.55, for a total transaction of $6,427,403.10. Following the completion of the transaction, the senior vice president now owns 78,582 shares of the company’s stock, valued at approximately $8,451,494.10. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jeffrey M. Leiden sold 296 shares of the company’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $106.66, for a total value of $31,571.36. Following the transaction, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $639,960. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 61,362 shares of company stock valued at $6,600,758. Insiders own 1.50% of the company’s stock.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply